The startup develops a clinical image analysis platform that utilizes AI technologies for medical image analysis and data mining, focusing on treatment effects in oncology and other therapeutic areas. By providing quantitative imaging and machine learning capabilities, the platform enhances clinical decision support, enabling healthcare professionals to deliver accurate diagnoses and tailored treatments.
Funding
$11.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The analysis of clinical images for oncology and other therapeutic areas often relies on subjective assessments, leading to variability in diagnoses and treatment decisions. Extracting comprehensive, quantitative data from these images is challenging, hindering the ability to personalize treatment and predict patient outcomes effectively.
Solution
Radiomics.bio provides an AI-powered platform that extracts quantitative data from standard-of-care medical images, enabling insight-based decision-making for healthcare professionals and pharmaceutical companies. The platform leverages radiomics, deep learning, and federated learning techniques to analyze images from various modalities, including CT, MRI, and PET scans. By identifying subtle signals of drug efficacy and safety risks, the platform optimizes clinical trials, facilitates go/no-go decisions, and identifies patients likely to respond to specific treatments. Radiomics.bio supports clients through all phases of clinical trials, from preclinical to post-market stages, and offers translational tools for optimized decision-making.
Target Audience
The primary target audience includes healthcare professionals (oncologists, radiologists), pharmaceutical companies conducting clinical trials, and scientific researchers in academia.
Features
- AI-powered image analysis using radiomics, deep learning, and federated learning
- Detection and phenotypic quantification of solid tumors
- Support for various imaging modalities: CT, MRI, PET, and Rx
- Identification of relevant biological pathways through radiomics-based imaging biomarkers
- Cloud-based infrastructure with containerization and auto-scaling technologies for high availability
- Compliance with ISO 13485 and ISO 27001 standards
- RadiomiX Research Toolbox for easy imaging data management, automated feature extraction, and machine learning